Dr. Xu Yufen | Drug Discovery and Development | Best Researcher Award

The Affiliated Hospital of Jiaxing University | China

Dr. Xu Yufen, Ph.D. in Medicine and Associate Professor at Jiaxing University, has emerged as a dedicated academic and clinical researcher in the field of chest tumors, with a strong focus on lung cancer, esophageal cancer, and thymoma. Her academic and professional journey reflects a unique blend of clinical insight and rigorous scientific research, bridging traditional and modern medical practices to address some of the most pressing challenges in oncology.Her research portfolio encompasses multiple completed and ongoing projects, including significant contributions to the Zhejiang Provincial Science and Technology Program in Traditional Chinese Medicine and Jiaxing City’s Science and Technology Program. Presently, she is leading three active research projects aimed at developing innovative therapeutic strategies and improving patient outcomes in chest oncology. Her studies demonstrate a strong commitment to integrating clinical experience with advanced research methodologies, paving the way for evidence-based, patient-centered cancer care.Dr. Xu’s scholarly impact is reflected in her extensive publication record in high-quality journals indexed in SCI and Scopus. Notable works include Development and Validation of a Prognostic Nomogram for Early Stage Non-Small Cell Lung Cancer: A Study Based on the SEER Database and a Chinese Cohort, Effect of Postoperative Radiotherapy on Survival in Patients with Completely Resected and Pathologically Confirmed Stage N2 Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis, LncRNA HCG11 Enhances the Chemosensitivity of Non-Small Cell Lung Cancer Cells to Gemcitabine via miR-17-5p/p21 Axis, and Akkermansia Muciniphila Outer Membrane Protein Regulates Recruitment of CD8+ T Cells in Lung Adenocarcinoma and Through JAK–STAT Signalling Pathway. These publications highlight her expertise in clinical oncology research, molecular biology, and the exploration of novel therapeutic targets.Her contributions to the academic community extend beyond research. Dr. Xu has been actively involved in professional organizations such as the Second Youth Committee of the Cancer Support Treatment Committee of the Zhejiang Society of Mathematical Medicine, the Chinese Society of Clinical Oncology’s expert committee on integrated traditional and Western medicine, and the Youth Committee of the Zhejiang Medical Association Oncology Branch. Through these roles, she fosters collaboration, knowledge-sharing, and the translation of research findings into clinical practice.

Profile: Scopus

Featured Publications

Authors Unknown. (2024). Akkermansia muciniphila outer membrane protein regulates recruitment of CD8+ T cells in lung adenocarcinoma and through JAK–STAT signalling pathway. Microbial Biotechnology.

Authors Unknown. (n.d.). Research progress in the therapeutic application of traditional Chinese medicine for postoperative cough in patients with lung cancer. Journal Name Unknown.

Authors Unknown. (n.d.). LncRNA HCG11 enhances the chemosensitivity of non-small cell lung cancer cells to Gemcitabine via miR-17-5p/p21 axis. Expert Review of Anticancer Therapy.